PMID-37900126 – BAM15 Mitochondrial Uncoupler Promising Therapeutic Agent Review
Jia M, Chen S, Zhang B, Liang H, Feng J, Zong Z. "BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases." Frontiers in Endocrinology, 2023;14:1252141.
Quick Reference
| Property | Value |
|---|---|
| PMID | 37900126 |
| DOI | 10.3389/fendo.2023.1252141 |
| Year | 2023 |
| Journal | Frontiers in Endocrinology |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | Review of preclinical literature |
| Peptide(s) Studied | BAM15 |
Key Findings
- Comprehensive review establishing BAM15 as a mitochondrial-selective protonophore with therapeutic potential across multiple disease states
- In obesity: BAM15 increases energy expenditure and reduces fat accumulation without reducing food intake or lean mass
- In diabetes: BAM15 improves glycemic control and reverses insulin resistance across multiple tissue types
- In NAFLD/MASH: BAM15 reduces hepatic steatosis and inflammatory lipid species
- In cancer (acute myeloid leukemia): BAM15 induces ROS production selectively in cancer cells, promoting apoptosis
- In neurodegeneration: BAM15 relieves neurodegeneration in aged C. elegans models and extends lifespan
- In inflammation: BAM15 attenuates LPS-induced inflammation in macrophages and hepatocytes
- Safety advantage over DNP: BAM15 does not depolarize the plasma membrane, has a wider therapeutic window, and does not cause hyperthermia
Study Design
Narrative review synthesizing all published BAM15 preclinical data across disease models. Organized by therapeutic area with mechanistic discussion of mitochondrial uncoupling pharmacology.
Limitations
- Narrative review format (not systematic); potential for selection bias
- All reviewed evidence is preclinical — no human clinical data exists for BAM15
- Some disease applications (cancer, neurodegeneration) based on single studies
- Long-term safety profile in chronic dosing remains unknown
Clinical Relevance
This review consolidates the therapeutic rationale for BAM15 across multiple indications. For the Ageless Peps context, the obesity and metabolic disease data are most relevant. The review highlights that BAM15 works via a completely different mechanism (energy expenditure via uncoupling) compared to GLP-1 agonists (appetite suppression), suggesting potential for combination approaches. The safety data consistently showing no hyperthermia or lean mass loss is encouraging for translation.
Related
#research #narrative-review #BAM15 #evidence-level-V